Achieve Life Sciences, Inc. (ACHV) is a specialty biopharmaceutical company dedicated to technological innovations to improve global health conditions. The company focuses primarily on the advancement and commercialization of drugs that cater to serious or life-threatening ailments. Incorporated in 1991 and headquartered in Seattle, Washington, ACHV has, for many years, conducted its operations through a network of scientists and researchers who bring forth innovative solutions to various health problems.
ACHV's flagship product, cytisine, is a plant-based alkaloid that is used to help smokers quit, an advancement that positions Achieve Life Sciences in a pivotal space within the public health concern of tobacco addiction. Cytisine is a naturally occurring plant-based alkaloid that has been used for more than five decades in Central and Eastern Europe in the treatment of nicotine addiction.
ACHV is committed to the development and provision of solutions that aid in smoking cessation. Its cytisine development program aims to deliver a lineup of products that can alleviate tobacco dependence, bolstering its position in the biopharmaceutical industry. Publicly traded on the NASDAQ, ACHV has enhanced its global reach over the years, evident in its significant foothold in the Canadian market and its collaborative relationship with University College London for clinical trials.
The company is guided by a board of members who bring in-depth knowledge and extensive experience in the development and commercialization of pharmaceutical products. This has driven the company’s success in research and development, investor relations, and strategic planning within a highly competitive pharmaceutical landscape.
With a coherent corporate social responsibility strategy, Achieve Life Sciences, Inc. is deeply committed to enhancing clinical outcomes and improving global health standards. The company’s dedication to addressing critical health challenges while maintaining robust corporate and social governance makes it a vanguard in the biopharmaceutical industry.
ACHV continues to invest in the development and endorsement of therapies which address significant health issues. By conducting rigorous clinical trials and maintaining high standards in all its operations, Achieve Life Sciences, Inc. continuously exhibits its commitment to technological innovation, health solutions, and value creation for its shareholders. The company's dedication to developing viable solutions for significant health conditions, like tobacco addiction, reflects its commitment to the betterment of public health and its robust corporate ethos.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Achieve Life Sciences (NASDAQ:ACHV) has received a consensus "Buy" rating from brokerages, with an average 12-month price target of $15.00, significantly higher than its opening price of $7.98. This positive outlook comes despite a recent earnings miss, where the company reported a quarterly EPS loss of $0.80 against an expected loss of $0.16. Institutional interest in ACHV has grown, with hedge funds and other investors increasing their stakes.
Bank of New York Mellon Corp has acquired 218,126 shares of Achieve Life Sciences, Inc. (NASDAQ:ACHV), a biopharmaceutical company, valued at approximately $1,424,000. Other institutional investors have also adjusted their stakes in ACHV, which currently has an average analyst rating of "Buy" with a target price of $15.00. The company's stock recently opened at $7.54, reflecting a 3.8% decline.
Wellington Management Group LLP recently acquired a new stake of 1.43 million shares in Achieve Life Sciences (NASDAQ:ACHV), valued at approximately $9.3 million, giving them a 1.39% ownership. This move is part of a broader trend of institutional investment, with firms like BlackRock and venBio Partners also initiating positions, bringing total institutional ownership to 33.52%. Despite a recent earnings miss and some bearish analyst ratings, the company maintains a consensus "Buy" rating and is developing cytisinicline for smoking cessation.
Frazier Life Sciences Management L.P. has acquired a new stake in Achieve Life Sciences, Inc. (NASDAQ:ACHV), purchasing over 7.6 million shares valued at approximately $49.7 million, making it their 19th-largest holding. Despite the company missing its quarterly earnings estimates, analysts maintain a broadly positive outlook with an average "Buy" rating and a $15 consensus price target. Institutional investors now own 33.5% of Achieve Life Sciences.
Achieve Life Sciences announced that its board of directors approved stock option grants for 315,000 shares and restricted stock unit (RSU) awards for 283,000 shares to seven new employees under its 2024 Equity Inducement Plan. These awards are part of an inducement package for new hires, with vesting periods set over four years. The company specializes in developing cytisinicline for nicotine dependence, including smoking and e-cigarette cessation.
Jupiter Topco LLC has acquired 2,751,032 shares of Achieve Life Sciences, Inc. (NASDAQ:ACHV) valued at approximately $17.96 million, giving it a 2.67% stake in the biopharmaceutical company. This new position contributes to the 33.52% of the company's stock owned by institutional investors and hedge funds. Despite a recent quarterly loss exceeding analyst expectations, analysts maintain a "Buy" consensus rating with an average target price of $15.00, though one "Sell" rating exists.
Achieve Life Sciences, Inc. (NASDAQ:ACHV) has received a consensus "Buy" rating from eight brokerages, with an average 12-month price target of $15.00. Despite missing quarterly earnings estimates, the stock has seen substantial growth within its 12-month range. Institutional ownership is significant at 33.52%, with new positions taken by several investment groups, although a company director recently sold shares.
A director at Achieve Life Sciences (NASDAQ: ACHV), Richard A. Stewart, recently sold US$175k worth of shares, representing 9.0% of his holding. This was the largest insider sale in the past year, though the sale occurred near the current share price of US$7.99, making it less concerning than sales at lower prices. Insiders currently own 2.3% of the company's shares.